Exact SciencesEXAS
EXAS
About: Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Employees: 6,600
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 14 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
125% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 9 (+5) [Q3]
107% more first-time investments, than exits
New positions opened: 120 | Existing positions closed: 58
63% more capital invested
Capital invested by funds: $7.81B [Q2] → $12.8B (+$4.94B) [Q3]
14% more call options, than puts
Call options by funds: $194M | Put options by funds: $170M
10% more funds holding
Funds holding: 530 [Q2] → 582 (+52) [Q3]
1.24% more ownership
Funds ownership: 100.2% [Q2] → 101.44% (+1.24%) [Q3]
15% less repeat investments, than reductions
Existing positions increased: 165 | Existing positions reduced: 195
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$60
16%
upside
Avg. target
$73
41%
upside
High target
$90
74%
upside
14 analyst ratings
14 positive
100%
0 neutral
0%
0 negative
0%
Benchmark Bruce Jackson 36% 1-year accuracy 19 / 53 met price target | 26%upside $65 | Buy Reiterated | 13 Jan 2025 |
B of A Securities Derik De Bruin 68% 1-year accuracy 13 / 19 met price target | 39%upside $72 | Buy Maintained | 13 Dec 2024 |
TD Cowen Dan Brennan 41% 1-year accuracy 12 / 29 met price target | 66%upside $86 | Buy Maintained | 26 Nov 2024 |
BTIG Mark Massaro 62% 1-year accuracy 18 / 29 met price target | 45%upside $75 | Buy Maintained | 26 Nov 2024 |
Piper Sandler David Westenberg 67% 1-year accuracy 26 / 39 met price target | 45%upside $75 | Overweight Maintained | 11 Nov 2024 |
Financial journalist opinion
Based on 6 articles about EXAS published over the past 30 days
Negative
Investors Business Daily
4 days ago
Exact Sciences Stock Drops 12% Over Four Days. 'What Is Going On?
Exact Sciences stock crumbled Thursday on its growing rivalry with Guardant Health and Natera in colon cancer screening. The post Exact Sciences Stock Drops 12% Over Four Days.
Positive
The Motley Fool
4 days ago
2 Healthcare Stocks to Buy Hand Over Fist in January
Stocks tend to perform well in January, but that's not a good reason to invest this month. Strong returns aren't made in a single 30-day period.
Positive
Benzinga
1 week ago
Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market
On Sunday, Exact Sciences Corp EXAS reported preliminary fiscal year 2024 sales of $2.76 billion, up 10% year-over-year, compared to consensus of $2.74 billion.
Neutral
Business Wire
1 week ago
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue of $713 million for the fourth quarter ended December 31, 2024. "The Exact Sciences team delivered strong results to finish 2024, setting us up for sustained growth and profitability in the years to come," said Kevin Conroy, chairman and CEO. "We look forward to expanding our impact as the platform supporting.
Positive
Zacks Investment Research
1 week ago
Should Exact Sciences Stock Stay in Your Portfolio Right Now?
EXAS' solid focus on expanding its lead Cologuard test and advancing new solutions bodes well for investors.
Neutral
Business Wire
2 weeks ago
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. J.P. Morgan Healthcare Conference, San Francisco Presentation followed by Q&A on Monday, January 13, 2025 at 1:30 p.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.
Neutral
GlobeNewsWire
1 month ago
AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates
ALEXANDRIA, Va., Dec. 09, 2024 (GLOBE NEWSWIRE) -- The American Academy of Physician Associates (AAPA) is proud to announce a new project, made possible through a grant from Exact Sciences, that aims to improve colorectal cancer screening rates.Physician associates/physician assistants (PAs) are often one of the first healthcare providers a patient sees, and thus are uniquely positioned to discuss screenings early on with patients.AAPA Chief Medical Officer Jennifer M. Orozco-Kolb, DMSc, PA-C, DFAAPA, said PAs play an important role in educating and encouraging patients to complete colorectal cancer screenings.“The 5-year survival rate for a patient who is diagnosed with colorectal cancer in the early stages is upward of 91%,” Orozco-Kolb said. “When a patient is diagnosed at a later stage, that survival rate drops to almost 14%. Screening through either at home DNA stool testing or traditional colonoscopy procedures should be considered when having conversations with patients about what works best for them.”The project consists of three phases. The first phase, which is underway, will feature focus group meetings with four federally qualified health centers (FQHCs) in Wisconsin and Arizona that previously received Exact Sciences funding to complete projects that improved colorectal cancer screening rates. These FQHCs were selected because they often serve underserved or uninsured patients who are less likely to access and complete colorectal cancer screenings.These focus group meetings are expected to be completed by February 2025, when the second phase of the project will begin. This phase involves taking lessons learned and best practices gathered during the focus groups and creating an innovative toolkit that can be widely used by providers across the country to improve their own colorectal cancer screening rates.The third phase will consist of taking the newly developed toolkit and implementing changes at select clinics across the country to measure outcomes.In 2024, the American Cancer Society ranked colorectal cancer as the third deadliest form of cancer in men, and fourth deadliest cancer in women. It's estimated that more than 152,000 people nationwide will be diagnosed with colorectal cancer this year.### Media Contacts: AAPA: Josh Birch, 443.614.5896 About the American Academy of Physician Associates (AAPA) AAPA is the national membership organization for all physician associates/physician assistants (PAs). PAs are licensed clinicians who practice medicine in every specialty and setting. Trusted, rigorously educated and trained healthcare professionals, PAs are dedicated to expanding access to care and transforming health and wellness through patient-centered, team-based medical practice. Learn more about the profession at aapa.org and engage through Facebook, LinkedIn, Instagram, and Twitter.
Neutral
Seeking Alpha
1 month ago
Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Exact Sciences Corporation (NASDAQ:EXAS ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 7:30 AM ET Company Participants Kevin Conroy - CEO Aaron Bloomer - CFO Conference Call Participants Vijay Kumar - Evercore Vijay Kumar Great. Thanks everyone for joining us this morning.
Neutral
Seeking Alpha
1 month ago
Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript)
Exact Sciences Corporation (NASDAQ:EXAS ) Citi's 2024 Global Healthcare Conference December 3, 2024 8:45 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - EVP, Finance Conference Call Participants Patrick Donnelly - Citi Patrick Donnelly Thanks, everybody, for joining us here at the conference. Happy to have Kevin Conroy and Aaron Bloomer from Exact Sciences with us here today.
Neutral
Business Wire
1 month ago
Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has teamed up with multi-platinum, Grammy award-winning artist Lil Jon on the “Get Low #2” campaign to increase screening for colon cancer, the nation's #2 cancer-related killer.2 The partnership also highlights the Cologuard® test as an effective, non-invasive tool to help improve screening rates for adults 45 and older who are eligible. The stool-based Cologuard test overcomes co.
Charts implemented using Lightweight Charts™